RARE
NASDAQ · Biotechnology
Ultragenyx Pharmaceutical In
$19.87
-0.55 (-2.69%)
Performance
1D
—
1W
—
1M
—
3M
-41.88%
6M
-31.67%
1Y
-48.64%
YTD
-15.81%
Open$20.52
Previous Close$20.42
Day High$20.68
Day Low$19.86
52W High$45.00
52W Low$18.41
Volume—
Avg Volume2.54M
Market Cap2.19B
P/E Ratio—
EPS$-5.84
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$26.56
Below
SMA 200
$31.06
Below
RSI (14)
37.4
Neutral
Trend
Death Cross
Bearish
Analyst Ratings
Strong Buy
27 analysts
Price Target
+274.6% upside
Current
$19.87
$19.87
Target
$74.44
$74.44
$68.49
$74.44 avg
$103.74
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 604.01M | 491.83M | 933.24M |
| Net Income | -516,053,134 | -378,184,040 | 54.30M |
| Profit Margin | -85.4% | -81.2% | 5.8% |
| EBITDA | -456,825,073 | -353,378,242 | 81.20M |
| Free Cash Flow | — | — | 84.57M |
| Rev Growth | +22.8% | +22.8% | -2.9% |
| Debt/Equity | 3.41 | 3.41 | 0.13 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $205.20 | +0.13% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $348.43 | -0.38% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.11 | +0.56% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $448.62 | -0.58% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $741.69 | +0.70% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $308.05 | +0.45% | 139.7 | 43.84B |